Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
Recruiting · NCT04271488 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants | Hepatic Impairment | Recruiting | Phase 1 | 2026-09-17 | NCT04271488 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eisai Co., Ltd. | 15 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Eisai Trial Site #1 | Mintato-ku | Japan | 1 |
| Eisai Trial Site #2 | Yuhu | Japan | 1 |
| Eisai Trial Site #3 | Bukyo-ku | Japan | 1 |
| Eisai Trial Site #4 | Kurume | Japan | 2 |
| Eisai Trial Site #5 | Kofu | Japan | 1 |
| Eisai Trial Site #6 | Hakata | Japan | 1 |
| Eisai Trial Site #7 | Kyoto | Japan | 1 |
| Eisai Trial Site #8 | Shinjuku-ku | Japan | 1 |